Image For Activity Cover
Developments in Molecular Testing and Systemic Therapies for Advanced and Metastatic NSCLC

Intended Audience: Oncology providers, including physicians, NPs, PAs, nurses, and pharmacists working in federal and public healthcare settings

Join us for this interactive live seminar, as renowned experts address the latest developments in molecular testing and systemic therapies for advanced or metastatic non-small cell lung cancer (NSCLC) in federal and public health settings.

This webinar features the latest evidence and insights on:

  • Targeted therapies and immunotherapies
  • Appropriate patient selection
  • Biomarker-driven decision-making
  • Interprofessional approaches for providing individualized, equitable, patient-centered care
Learning Objectives
  • Assess the role of predictive and prognostic molecular biomarkers in guiding treatment decisions for patients with advanced lung cancer
  • Integrate new clinical evidence and guideline recommendations on targeted agents and immunotherapies into treatment plans for patients with advanced lung cancer
  • Evaluate emerging systemic therapies for patients with advanced lung cancer
  • Implement evidence-based strategies for reducing disparities in care access and treatment in federal and public health settings
  1. Molecular Testing in NSCLC: Current Guidelines on How and When to Test and What to Test for
  2. Selecting and Sequencing Therapies in Patients With NSCLC Carrying Actionable Mutations
  3. Evidence-Based Selection of Immunotherapies for NSCLC Based on Biomarker Testing Results
  4. Emerging Systemic Therapies for Advanced and Metastatic NSCLC
  5. Practical Strategies for Recognizing and Addressing Disparities in NSCLC Molecular Testing and Treatment

Michael J Kelley, MD, FACP

Michael J Kelley, MD, FACP

Professor of Medicine
Duke University School of Medicine
Chief, Hematology-Oncology
Durham VA Medical Center
National Program Director for Oncology
Department of Veterans Affairs
Durham, NC

Drew Moghanaki, MD, MPH

Drew Moghanaki, MD, MPH

Professor and Chief, Thoracic Oncology Service
Department of Radiation Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Douglas S Burgoyne, PharmD, FAMCP

Douglas S Burgoyne, PharmD, FAMCP

Adjunct Associate Professor
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT

Mark A Rubin, MD


Medical Director
Fort Lauderdale, FL

Ryan M Burke, PharmD


Director, Professional Affairs
Pharmacy Technician Certification Board
Washington, DC

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Peer Reviewer

Adult Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, IN

CE Details & Instructions

Joint Accreditation Statement

IPCE Credit™
In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Teams

Joint AccreditationThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement


PRIME® designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

MOC Points

ACCME MOC LogoSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Physician Assistant Accreditation Statement


PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

Nurse Practitioner LogoPRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0 hour of pharmacology).

Pharmacist Accreditation Statement


This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-200-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).

Nurse Accreditation Statement


PRIME® designates this activity for 1.0 contact hour.

Obtaining CE Credit
  1. Register using the online form
  2. Complete the pre-registration survey
  3. Attend the live program in its entirety
  4. Complete an online evaluation and post-test
  5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

Method of Participation
This live CME/CE activity requires attendance of the participant during the entire program and completion of learner assessment tools. The learner will then receive instructions on how to download and/or print a certificate of completion and/or submit CE credits electronically.
Device Requirements
  • Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
  • Software: the installation of software such as GoToWebinar may be required
Faculty Disclosures

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

  • Michael J Kelley, MD, FACP (Speaker)
    Grants / Research Support – AstraZenecaBristol-Myers Squibb FoundationGenentechNovartis
    Other Financial or Material Support (royalties, patents, etc.) – IBM
  • Drew Moghanaki, MD, MPH (Speaker)
    Advisory Board or Panel – AccurayAstraZeneca
    Other Financial or Material Support (royalties, patents, etc.) – Varian Medical SystemsViewRay
  • Jane Lowe Meisel, MD (Speaker)
    Advisory Board or Panel – AstraZenecaEli Lilly and CompanyGlaxoSmithKlineNovartisSanofi GenzymeSeagen
  • Sara A Hurvitz, MD, FACP (Speaker)
    Grants / Research Support – AmbryxAmgenArvinasAstraZenecaBayerDaiichi SankyoDignitanaGenentechGlaxoSmithKlineImmunomedicsLillyLtdMacrogenicsNKMaxNovartisOBI Pharma Inc.PfizerPhoenix Molecular DesignsPierisPuma BiotechnologyRadiusZymeworks
    Stock / Shareholder (self- managed) – NKMax
  • Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Reviewer)
    Speakers Bureau or other Promotional Education – AstellasAstraZenecaBristol-Myers SquibbCoherusDSIDovaEli Lilly and CompanyGilead SciencesMorphosysPfizer

The following individuals have no relevant financial relationships with commercial interests to disclose:

  • Douglas S Burgoyne, PharmD, FAMCP (Moderator)
  • Mark A Rubin, MD (Planner)
  • Ryan M Burke, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.

Funding Disclosure
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., Genentech, and Merck & Co., Inc.
Accessibility Statement
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing, please email [email protected] for assistance. Please put "ADA Inquiry" in the subject line of your email.
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
             Submit a Support Ticket
             Write Us a Friendly Review